The influence of teriparatide in induced tooth movement: A systematic review

Abstract

BackgroundTeriparatide is a synthetic drug similar than PTH (parathyroid hormone), which is currently used as long-term treatment option for patients with bone chronic diseases, as osteoporosis; and this drug can interfere in a positive way in orthodontic movement. Objectives: The medical literature was assessed in the present systematic review in order to determine the level of scientific evidence supporting the influence of teriparatide in induced tooth movement.Material and MethodsThe PRISMA Checklist was followed in this systematic review. Four electronic databases (PubMed; Scopus; ScienceDirect; OpenGrey) were searched without implementing restrictions of year, status, and language of publications. The inclusion criteria consisted of selecting only experimental studies comparing the influence of teriparatide in tooth movement of male Wistar rats. The exclusion criteria consisted of experiments with female rats or other experimental animals, and animals with pathologic conditions. The eligible studies were evaluated based on methodological quality. Two trained examiners performed all the research steps.ResultsThe initial sample comprised 700 studies, which was reduced to 664 after the exclusion of duplicates (n=36). Three articles were selected for the final qualitative analysis. The local administration of parathyroid hormone (PTH) 1-34 or PTH 1-84 revealed major effectiveness when compared with control groups and systematic administration. Additionally, the dilution of PTH 1-34 within methyl cellulose (MC) gel increased the time range for drug release, enabling to reduce the drug concentration without decreasing the effectiveness of tooth movement.ConclusionsTeriparatide demonstrated potential acceleration of tooth movement in Wistar rats depending on the drug concentration; drug administration; and time for drug release. Key words:Teriparatide, tooth movement, parathyroid hormone, orthodontics.

Lithium chloride promotes osteogenesis and suppresses apoptosis during orthodontic tooth movement in osteoporotic model via regulating autophagy

“…At present, parathyroid hormone (PTH) [ 43 ], bisphosphonates [ 44 ] and alendronate [ 39 ] are common drugs for treating osteoporosis in the clinic. It has been demonstrated that these medicines have bidirectional regulatory effects that simultaneously inhibit osteoclastic activity and promote osteogenesis.…”

Effects of teriparatide on bone formation in rats with experimentally induced premaxillary expansion

“…Furthermore, we used systemically administration of teriparatide 27 , 28 rather than a local injection, as suggested in the literature, during orthodontic treatment, because of the possibility of a direct effect on the osteoblasts. 43 Local administration was reported to fail because it could not specifically target the osteoblastic activity. 3 , 39 The ease of application, the vascular structure of the maxilla, and the wide use of systemic administration in the literature makes it a more effective method than local injection.…”

Effects of the different administration frequencies of teriparatide (PTH [1‐34]) on new bone formation of expanded midpalatal sutures in rats: A histomorphometric and micro‐computed tomography analysis

“…Teriparatide is used in clinical and animal studies in many areas of dentistry. [26][27][28][29] One of the main factors that determines the effectiveness of TP is the frequency of administration, and intermittent administration of TP has been found to promote osteoblastic and osteoclastic activities simultaneously. 30 While intermittent administration of TP induces the maturation of circulating osteoblast precursors and differentiation of lining osteoblasts leading to an increase in osteoblasts, it focuses on prevention of osteoblast apoptosis, enhanced mineral apposition rate and osteoblast activity and improvement of bone microarchitecture, while enhancing bone formation.…”